Evidence map›Paper›PMID 36521930›Full record

ArticleJournal for immunotherapy of cancer2022

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19

Christopher A Pennell, Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, Mark J Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S Young, Bruce R Blazar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Modular (universal) CAR-T platformsFrontiers in immunology · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Christopher A PennellLaboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA penne001@umn.edu.ORCID 0000-0002-2901-6554
Heather CampbellLaboratory Medicine and Pathology, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
Meghan D StorlieLaboratory Medicine and Pathology, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
Sara Bolivar-WagersDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
Mark J OsbornDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
Yosef RefaeliDepartment of Dermatology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.
Michael JensenBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Sophie ViaudCalibr, The Scripps Research Institute, La Jolla, California, USA.
Travis S Young *Calibr, The Scripps Research Institute, La Jolla, California, USA.
Bruce R Blazar *Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
University of Minnesota · USScripps Research Institute · USSeattle Children's Hospital · USUniversity of Colorado Denver · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Bruce R Blazar · 1995 to 2026
$48.2M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cellsR01CA263090 · NCI · UNIVERSITY OF MINNESOTA · PI CHRISTOPHER A PENNELL · 2022 to 2026
$2.7M
CAR-T cell control through orthogonal antibody-based switchesR01CA208398 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI YOUNG, TRAVIS SCOTT · 2016 to 2020
$1.9M
Enhancing Treg Therapeutic Efficacy in GVHD with CARsF30HL156312 · NHLBI · UNIVERSITY OF MINNESOTA · PI BOLIVAR WAGERS, SARA · 2021 to 2023
$110k
NCI NIH HHS P01 CA065493NCI NIH HHS R01 CA208398NCI NIH HHS R01 CA263090NHLBI NIH HHS F30 HL156312NHLBI NIH HHS R01 HL056067NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be reduced if CAR T-cell activity was regulatable rather than constitutive. To test this, we compared the efficacies and morbidities of constitutively active (conventional) and regulatable (switchable) CAR (sCAR) T-cells specific for human CD19 (huCD19) in an immune-competent huCD19

Indexed as

Antigens, CD19Lymphoma, B-CellAnimalsDisease Models, AnimalHumansMiceMice, Inbred C57BLMice, TransgenicMorbidityReceptors, Antigen, T-CellT-LymphocytesUnited StatesWeight LossAntigens, CD19CD19-specific chimeric antigen receptorReceptors, Antigen, T-CellCell EngineeringCytotoxicity, ImmunologicHematologic NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric Antigen

Identifiers

PMID36521930
PMCPMC9756162
OpenAlexW4311806323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.